233 related articles for article (PubMed ID: 15031473)
21. The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine.
Foekens JA; Wang Y; Martens JW; Berns EM; Klijn JG
Drug Discov Today; 2008 Jun; 13(11-12):481-7. PubMed ID: 18549973
[TBL] [Abstract][Full Text] [Related]
22. Genomic strategies for personalized cancer therapy.
Garman KS; Nevins JR; Potti A
Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R226-32. PubMed ID: 17911165
[TBL] [Abstract][Full Text] [Related]
23. A pathologist's perspective on emerging genomic tests for breast cancer.
Symmans WF
Semin Oncol; 2007 Apr; 34(2 Suppl 3):S4-9. PubMed ID: 17512433
[TBL] [Abstract][Full Text] [Related]
24. Genomics in breast cancer-therapeutic implications.
Lønning PE; Sørlie T; Børresen-Dale AL
Nat Clin Pract Oncol; 2005 Jan; 2(1):26-33. PubMed ID: 16264853
[TBL] [Abstract][Full Text] [Related]
25. Predicting features of breast cancer with gene expression patterns.
Lu X; Lu X; Wang ZC; Iglehart JD; Zhang X; Richardson AL
Breast Cancer Res Treat; 2008 Mar; 108(2):191-201. PubMed ID: 18297396
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy].
Diallo-Danebrock R; Ting E; Gluz O; Herr A; Mohrmann S; Geddert H; Gabbert HE; Nitz U; Poremba C
Verh Dtsch Ges Pathol; 2007; 91():187-96. PubMed ID: 18314614
[TBL] [Abstract][Full Text] [Related]
27. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
28. Genetics and medicine. Putting gene arrays to the test.
Branca M
Science; 2003 Apr; 300(5617):238. PubMed ID: 12690165
[No Abstract] [Full Text] [Related]
29. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.
Weigelt B; Hu Z; He X; Livasy C; Carey LA; Ewend MG; Glas AM; Perou CM; Van't Veer LJ
Cancer Res; 2005 Oct; 65(20):9155-8. PubMed ID: 16230372
[TBL] [Abstract][Full Text] [Related]
30. Molecular markers of breast axillary lymph node metastasis.
Cavalli LR
Expert Rev Mol Diagn; 2009 Jul; 9(5):441-54. PubMed ID: 19580429
[TBL] [Abstract][Full Text] [Related]
31. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy.
Paik S
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1019s-1023s. PubMed ID: 16467119
[TBL] [Abstract][Full Text] [Related]
32. Road map to metastasis.
Van't Veer LJ; Weigelt B
Nat Med; 2003 Aug; 9(8):999-1000. PubMed ID: 12894162
[No Abstract] [Full Text] [Related]
33. Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
[TBL] [Abstract][Full Text] [Related]
34. A six-gene signature predicting breast cancer lung metastasis.
Landemaine T; Jackson A; Bellahcène A; Rucci N; Sin S; Abad BM; Sierra A; Boudinet A; Guinebretière JM; Ricevuto E; Noguès C; Briffod M; Bièche I; Cherel P; Garcia T; Castronovo V; Teti A; Lidereau R; Driouch K
Cancer Res; 2008 Aug; 68(15):6092-9. PubMed ID: 18676831
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
36. [Histopathologic diagnosis of luminal and basal type breast cancer].
Sarcević B
Acta Med Croatica; 2008 Oct; 62(4):427-30. PubMed ID: 19205420
[TBL] [Abstract][Full Text] [Related]
37. C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.
Diallo R; Ting E; Gluz O; Herr A; Schütt G; Geddert H; Mohrmann S; Gabbert HE; Nitz U; Poremba C
Verh Dtsch Ges Pathol; 2006; 90():177-85. PubMed ID: 17867595
[TBL] [Abstract][Full Text] [Related]
38. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics.
Chen W; Salto-Tellez M; Palanisamy N; Ganesan K; Hou Q; Tan LK; Sii LH; Ito K; Tan B; Wu J; Tay A; Tan KC; Ang E; Tan BK; Tan PH; Ito Y; Tan P
Genes Chromosomes Cancer; 2007 Mar; 46(3):288-301. PubMed ID: 17171680
[TBL] [Abstract][Full Text] [Related]
39. Microarrays: retracing steps.
Coombes KR; Wang J; Baggerly KA
Nat Med; 2007 Nov; 13(11):1276-7; author reply 1277-8. PubMed ID: 17987014
[No Abstract] [Full Text] [Related]
40. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu LA; Zerba KE; Lee H; Clark E; Galbraith S
J Clin Oncol; 2009 Feb; 27(4):526-34. PubMed ID: 19075286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
